vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and FIRST INTERSTATE BANCSYSTEM INC (FIBK). Click either name above to swap in a different company.
FIRST INTERSTATE BANCSYSTEM INC is the larger business by last-quarter revenue ($313.0M vs $284.0M, roughly 1.1× ACADIA PHARMACEUTICALS INC). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs 34.8%, a 61.6% gap on every dollar of revenue. On growth, FIRST INTERSTATE BANCSYSTEM INC posted the faster year-over-year revenue change (19.8% vs 9.4%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs 13.7%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
First Interstate BancSystem, Inc. is a financial holding company headquartered in Billings, Montana. It is the parent company of First Interstate Bank, a community bank with locations throughout 14 states within the Western and Midwestern United States. It is the largest bank based in Montana, as measured by total assets.
ACAD vs FIBK — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $313.0M |
| Net Profit | $273.6M | $108.8M |
| Gross Margin | 90.8% | — |
| Operating Margin | 6.1% | 44.5% |
| Net Margin | 96.3% | 34.8% |
| Revenue YoY | 9.4% | 19.8% |
| Net Profit YoY | 90.3% | 108.8% |
| EPS (diluted) | $1.61 | $1.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $313.0M | ||
| Q3 25 | $278.6M | $250.5M | ||
| Q2 25 | $264.6M | $248.3M | ||
| Q1 25 | $244.3M | $247.0M | ||
| Q4 24 | $259.6M | $261.3M | ||
| Q3 24 | $250.4M | $251.9M | ||
| Q2 24 | $242.0M | $244.3M | ||
| Q1 24 | $205.8M | $242.2M |
| Q4 25 | $273.6M | $108.8M | ||
| Q3 25 | $71.8M | $71.4M | ||
| Q2 25 | $26.7M | $71.7M | ||
| Q1 25 | $19.0M | $50.2M | ||
| Q4 24 | $143.7M | $52.1M | ||
| Q3 24 | $32.8M | $55.5M | ||
| Q2 24 | $33.4M | $60.0M | ||
| Q1 24 | $16.6M | $58.4M |
| Q4 25 | 90.8% | — | ||
| Q3 25 | 92.2% | — | ||
| Q2 25 | 92.2% | — | ||
| Q1 25 | 91.7% | — | ||
| Q4 24 | 91.6% | — | ||
| Q3 24 | 92.5% | — | ||
| Q2 24 | 92.5% | — | ||
| Q1 24 | 88.8% | — |
| Q4 25 | 6.1% | 44.5% | ||
| Q3 25 | 12.8% | 37.0% | ||
| Q2 25 | 12.2% | 37.7% | ||
| Q1 25 | 7.9% | 26.9% | ||
| Q4 24 | 59.1% | 25.5% | ||
| Q3 24 | 12.6% | 28.9% | ||
| Q2 24 | 12.6% | 32.1% | ||
| Q1 24 | 7.4% | 31.7% |
| Q4 25 | 96.3% | 34.8% | ||
| Q3 25 | 25.8% | 28.5% | ||
| Q2 25 | 10.1% | 28.9% | ||
| Q1 25 | 7.8% | 20.3% | ||
| Q4 24 | 55.4% | 19.9% | ||
| Q3 24 | 13.1% | 22.0% | ||
| Q2 24 | 13.8% | 24.6% | ||
| Q1 24 | 8.0% | 24.1% |
| Q4 25 | $1.61 | $1.07 | ||
| Q3 25 | $0.42 | $0.69 | ||
| Q2 25 | $0.16 | $0.69 | ||
| Q1 25 | $0.11 | $0.49 | ||
| Q4 24 | $0.86 | $0.50 | ||
| Q3 24 | $0.20 | $0.54 | ||
| Q2 24 | $0.20 | $0.58 | ||
| Q1 24 | $0.10 | $0.57 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | — |
| Total DebtLower is stronger | — | $146.3M |
| Stockholders' EquityBook value | $1.2B | $3.4B |
| Total Assets | $1.6B | $26.6B |
| Debt / EquityLower = less leverage | — | 0.04× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | — | ||
| Q3 25 | $258.0M | — | ||
| Q2 25 | $253.6M | — | ||
| Q1 25 | $217.7M | — | ||
| Q4 24 | $319.6M | — | ||
| Q3 24 | $155.1M | — | ||
| Q2 24 | $177.1M | — | ||
| Q1 24 | $204.7M | — |
| Q4 25 | — | $146.3M | ||
| Q3 25 | — | $146.2M | ||
| Q2 25 | — | $252.0M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $132.2M | ||
| Q3 24 | — | $137.3M | ||
| Q2 24 | — | $383.4M | ||
| Q1 24 | — | $370.8M |
| Q4 25 | $1.2B | $3.4B | ||
| Q3 25 | $917.3M | $3.4B | ||
| Q2 25 | $822.4M | $3.4B | ||
| Q1 25 | $765.2M | $3.4B | ||
| Q4 24 | $732.8M | $3.3B | ||
| Q3 24 | $577.2M | $3.4B | ||
| Q2 24 | $516.7M | $3.2B | ||
| Q1 24 | $464.0M | $3.2B |
| Q4 25 | $1.6B | $26.6B | ||
| Q3 25 | $1.3B | $27.3B | ||
| Q2 25 | $1.2B | $27.6B | ||
| Q1 25 | $1.1B | $28.3B | ||
| Q4 24 | $1.2B | $29.1B | ||
| Q3 24 | $976.9M | $29.6B | ||
| Q2 24 | $914.1M | $30.3B | ||
| Q1 24 | $855.1M | $30.1B |
| Q4 25 | — | 0.04× | ||
| Q3 25 | — | 0.04× | ||
| Q2 25 | — | 0.07× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.04× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.12× | ||
| Q1 24 | — | 0.12× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $305.6M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | -0.18× | 2.81× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $305.6M | ||
| Q3 25 | $74.3M | $91.7M | ||
| Q2 25 | $64.0M | $68.1M | ||
| Q1 25 | $20.3M | $78.5M | ||
| Q4 24 | $40.4M | $355.0M | ||
| Q3 24 | $63.2M | $89.9M | ||
| Q2 24 | $25.0M | $82.3M | ||
| Q1 24 | $29.1M | $87.6M |
| Q4 25 | — | — | ||
| Q3 25 | $73.9M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $63.2M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 26.5% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 25.2% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -0.18× | 2.81× | ||
| Q3 25 | 1.03× | 1.28× | ||
| Q2 25 | 2.40× | 0.95× | ||
| Q1 25 | 1.07× | 1.56× | ||
| Q4 24 | 0.28× | 6.81× | ||
| Q3 24 | 1.93× | 1.62× | ||
| Q2 24 | 0.75× | 1.37× | ||
| Q1 24 | 1.76× | 1.50× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
FIBK
Segment breakdown not available.
